Claim 1: an oral medicine composition, comprising: (a) a fat derivative represented by formula (1), wherein L, m and N are hydrogen, hydrogen Xi, halogen, lower hydrocarbon, lower hydroxide or oxo, wherein at least one l and m are different hydrogen groups, The rings of five members have at least one double link, a es-ch832323,O-ch8322；, oh, coch8322；, oh, COOH or a functional derivative of these products； B is a single link, - ch832222 -；-CH=CH---C...-CH₂-CH₂-CH₂-,-CH = CH-CH₂-,-CH₂-CH = CH-,-C ° C-CH₂- or -CH₂-C ° C；Z is a compound composed of formula (2) or a single link group, wherein r83088 and r83099 are hydrogen, hydrogen Xi, halogen, low hydrocarbon, low oxygen or lower hydroxide, wherein r830808 and r830909 are not hydrogen Xi and alcox at the same time； R1 is an unsaturated or unsaturated or unsaturated middle, low or unsaturated / or unsaturated liquefied hydrogen carbide residue； a. It can be replaced or replaced by halogen, low tar, hydrogen Xi, oxo, arilo or heterocyclic cyclic group, and at least one carbon atom in the solution can be replaced by oxygen, nitrogen or sulfur； r74919 is a saturated or unsaturated or unsaturated medium or low flow oil；which is not substituted or substituted by halogen, oxo, hydroxy, lower alkyl, lower alkoxy, lower alkanoyloxy, lower cycloalkyl, lower cycloalkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group； lower alkoxy； lower alkanoyloxy； lower cycloalkyl； lower cycloalkyloxy； aryl； aryloxy； heterocyclic group； heterocyclic-oxy group, and at least one of the carbon atoms in the aliphatic hydrocarbon is optionally substituted with oxygen, nitrogen or sulfur； (b) a sweetening agent selected from the group consisting of neotame, saccharin, sucralose and one of their mixtures；and (c) a pharmaceutically acceptable oily vehicle. Claim 6: The composition as described in claim 1, wherein the fatty acid derivative is (-) - 7 - [(2R, 4aR, 5R, 7aR) -2- (1,1-difluoropentyl) -2- hydroxy-6-oxooctahydrocyclopenta [b
